Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasm Metastasis × sarilumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 2 Fallopian Tube Neoplasms 2 Endometrial Neoplasms 2 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Metastatic Castration-resistant Prostate Cancer 1

Interventions

pembrolizumab 36 Nivolumab 20 Gemcitabine 18 Paclitaxel 17 Cyclophosphamide 17 Capecitabine 16 fludarabine 11 aldesleukin 11 Ipilimumab 11 130-nm albumin-bound paclitaxel 10 Docetaxel 9 Trastuzumab 8 Albumin-Bound Paclitaxel 8 Radiosurgery 7 Interleukin-2 7 Biopsy 7 Bevacizumab 7 fludarabine phosphate 6 Temozolomide 6 Specimen Handling 6 Irinotecan 6 Fluorouracil 6 Cisplatin 6 Cetuximab 6 Carboplatin 6 avelumab 5 Radiotherapy 5 Pemetrexed 5 Oxaliplatin 5 Magnetic Resonance Spectroscopy 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04333706 2026-03-10

EMPOWER

University of Southern California

Phase 1/2 Recruiting

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡